The detection and management of MNTs following BCMA-directed CAR-T therapy

Can a patient use a different CAR-T target after receiving BCMA directed therapy?Подробнее

PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myelomaПодробнее

Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cellsПодробнее

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhDПодробнее

Predictors of T Cell Expansion and Clinical Responses Following CART-BCMA for RRMMПодробнее

CAR T-cells directed against BCMA in MMПодробнее

BCMA-Directed CAR T-Cell Therapy: OutlookПодробнее

Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myelomaПодробнее

Integrating BCMA-directed bispecifics and CAR-T into the myeloma treatment landscapeПодробнее

The management & optimization of CAR T-cell therapy in myelomaПодробнее

CAR T-Cell Therapy for Multiple MyelomaПодробнее

CAR T-cells: targeting BCMAПодробнее

BCMA-targeting CAR-T: lessons moving forwardПодробнее

BCMA-Targeted CAR T-Cell Therapy for MyelomaПодробнее

Clinical Trial: BCMA CAR T Cell Trial with Adam Cohen, MD, University PennsylvaniaПодробнее

Dr. Michael Chu on Orvacabtagene autoleucel, a BCMA-directed CAR T-cell therapy for R/R multiple...Подробнее

CAR-T therapy in multiple myeloma: research blind spotsПодробнее

BCMA-Directed CAR T-Cell Therapy: Next Steps in ResearchПодробнее

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple MyelomaПодробнее